Nexalin Technology (NASDAQ:NXL) Announces Quarterly Earnings Results

Nexalin Technology (NASDAQ:NXL – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($3.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.91) by ($0.52), FiscalAI reports. Nexalin Technology had a negative return on equity of 278.24% and a negative net margin of 4,141.94%. The business had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.07 million.

Nexalin Technology Stock Down 6.3%

NASDAQ:NXL traded down $0.10 during trading hours on Thursday, hitting $1.49. The stock had a trading volume of 14,613 shares, compared to its average volume of 43,979. Nexalin Technology has a 1-year low of $1.31 and a 1-year high of $39.30. The business has a 50 day simple moving average of $3.42 and a two-hundred day simple moving average of $10.18.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Zacks Research raised shares of Nexalin Technology to a “hold” rating in a research report on Thursday, October 1st. Weiss Ratings lowered shares of Nexalin Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 25th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce”.

Get Our Latest Stock Analysis on Nexalin Technology

About Nexalin Technology

(Get Free Report)

Nexalin Technology, Inc. (NASDAQ:NXL) is a medical technology company focused on developing and commercializing noninvasive neurostimulation devices for mental health and neurological applications. Its technology is designed to deliver low-intensity electrical stimulation to the brain with the goal of influencing neural activity associated with conditions such as depression, anxiety, insomnia, post-traumatic stress disorder and substance-use disorders. The company’s product portfolio includes the Gen-2 and Gen-3 neurostimulation systems.

Featured Stories

Earnings History for Nexalin Technology (NASDAQ:NXL)

Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.